Literature DB >> 14758079

90K (Mac-2 BP) and galectins in tumor progression and metastasis.

Antonino Grassadonia1, Nicola Tinari, Ida Iurisci, Enza Piccolo, Alba Cumashi, Pasquale Innominato, Maurizia D'Egidio, Clara Natoli, Mauro Piantelli, Stefano Iacobelli.   

Abstract

Galectins and their ligands have been implicated in cell transformation and cancer metastasis, and found to have prognostic value. Mac-2 BP, also known as 90K, is a highly glycosylated, secreted protein extensively studied in human cancer, which binds galectin-1, galectin-3 and galectin-7. High expression levels of 90K are associated with a shorter survival, the occurrence of metastasis or a reduced response to chemotherapy in patients with different types of malignancy. The mechanisms underlying the prognostic significance of 90K and galectins in cancer are far from being understood, although they may be related to the ability of these proteins to interact and, to some extent, modulate cell-cell and cell-matrix adhesion and apoptosis. The resulting scenario is even more complex, as data have been presented that all these proteins might be associated with either a positive or a negative outcome of the patients. It is hypothesised that different galectins and galectin ligands with overlapping or opposite functions, expressed in different tumors during the different steps of the metastatic cascade might play a crucial role in tumor progression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 14758079     DOI: 10.1023/B:GLYC.0000014085.00706.d4

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   2.916


  60 in total

1.  Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma.

Authors:  D K Hsu; C A Dowling; K C Jeng; J T Chen; R Y Yang; F T Liu
Journal:  Int J Cancer       Date:  1999-05-17       Impact factor: 7.396

2.  Decreased expression of galectin-3 is associated with progression of human breast cancer.

Authors:  V Castronovo; F A Van Den Brûle; P Jackers; N Clausse; F T Liu; C Gillet; M E Sobel
Journal:  J Pathol       Date:  1996-05       Impact factor: 7.996

3.  The levels of expression of galectin-1, galectin-3, and the Thomsen-Friedenreich antigen and their binding sites decrease as clinical aggressiveness increases in head and neck cancers.

Authors:  G Choufani; N Nagy; S Saussez; H Marchant; P Bisschop; M Burchert; A Danguy; S Louryan; I Salmon; H J Gabius; R Kiss; S Hassid
Journal:  Cancer       Date:  1999-12-01       Impact factor: 6.860

4.  Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.

Authors:  H Lahm; S André; A Hoeflich; J R Fischer; B Sordat; H Kaltner; E Wolf; H J Gabius
Journal:  J Cancer Res Clin Oncol       Date:  2001       Impact factor: 4.553

5.  Galectin-3 expression in human breast carcinoma: correlation with cancer histologic grade.

Authors:  H Idikio
Journal:  Int J Oncol       Date:  1998-06       Impact factor: 5.650

6.  Circulating immunostimulatory protein 90K and soluble interleukin-2-receptor in human ovarian cancer.

Authors:  A G Zeimet; C Natoli; M Herold; D Fuchs; G Windbichler; G Daxenbichler; S Iacobelli; O Dapunt; C Marth
Journal:  Int J Cancer       Date:  1996-09-27       Impact factor: 7.396

7.  Suppression of tumor growth in vivo by local and systemic 90K level increase.

Authors:  B Jallal; J Powell; J Zachwieja; C Brakebusch; L Germain; J Jacobs; S Iacobelli; A Ullrich
Journal:  Cancer Res       Date:  1995-08-01       Impact factor: 12.701

8.  Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer.

Authors:  S Iacobelli; E Arnò; A D'Orazio; G Coletti
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701

9.  Measurement of a breast cancer associated antigen detected by monoclonal antibody SP-2 in sera of cancer patients.

Authors:  S Iacobelli; E Arno; P Sismondi; C Natoli; N Gentiloni; G Scambia; M Giai; P Cortese; P B Panici; S Mancuso
Journal:  Breast Cancer Res Treat       Date:  1988-04       Impact factor: 4.872

10.  Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease.

Authors:  C Natoli; C Garufi; N Tinari; M D'Egidio; G Lesti; L A Gaspari; R Visini; S Iacobelli
Journal:  Br J Cancer       Date:  1993-03       Impact factor: 7.640

View more
  65 in total

1.  Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) recognizes a novel ligand, Mac-2-binding protein, characteristically expressed on human colorectal carcinomas.

Authors:  Motohiro Nonaka; Bruce Yong Ma; Hirotsugu Imaeda; Keiko Kawabe; Nobuko Kawasaki; Keiko Hodohara; Nana Kawasaki; Akira Andoh; Yoshihide Fujiyama; Toshisuke Kawasaki
Journal:  J Biol Chem       Date:  2011-04-22       Impact factor: 5.157

Review 2.  Introduction to galectins.

Authors:  Hakon Leffler; Susanne Carlsson; Maria Hedlund; Yuning Qian; Francoise Poirier
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

3.  Shoc2-tranduced ERK1/2 motility signals--Novel insights from functional genomics.

Authors:  Myoungkun Jeoung; Eun Ryoung Jang; Jinpeng Liu; Chi Wang; Eric C Rouchka; Xiaohong Li; Emilia Galperin
Journal:  Cell Signal       Date:  2016-02-11       Impact factor: 4.315

4.  Co-purification of Mac-2 binding protein with galectin-3 and association with prostasomes in human semen.

Authors:  Ashley S Block; Sarika Saraswati; Cheryl F Lichti; Maha Mahadevan; Alan B Diekman
Journal:  Prostate       Date:  2010-10-28       Impact factor: 4.104

5.  Tumor biomarker glycoproteins in the seminal plasma of healthy human males are endogenous ligands for DC-SIGN.

Authors:  Gary F Clark; Paola Grassi; Poh-Choo Pang; Maria Panico; David Lafrenz; Erma Z Drobnis; Michael R Baldwin; Howard R Morris; Stuart M Haslam; Sophia Schedin-Weiss; Wei Sun; Anne Dell
Journal:  Mol Cell Proteomics       Date:  2011-10-10       Impact factor: 5.911

Review 6.  Carbohydrate recognition by boronolectins, small molecules, and lectins.

Authors:  Shan Jin; Yunfeng Cheng; Suazette Reid; Minyong Li; Binghe Wang
Journal:  Med Res Rev       Date:  2010-03       Impact factor: 12.944

7.  Identification of Mac-2-binding protein as a putative marker of neuroendocrine tumors from the analysis of cell line secretomes.

Authors:  Rajaventhan Srirajaskanthan; Martyn E Caplin; Mark G Waugh; Jennifer Watkins; Tim Meyer; J Justin Hsuan; Nicholas J Beaumont
Journal:  Mol Cell Proteomics       Date:  2009-12-17       Impact factor: 5.911

8.  Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry.

Authors:  Alexandra A Mourad-Zeidan; Vladislava O Melnikova; Hua Wang; Avraham Raz; Menashe Bar-Eli
Journal:  Am J Pathol       Date:  2008-11-06       Impact factor: 4.307

9.  LGALS3BP regulates centriole biogenesis and centrosome hypertrophy in cancer cells.

Authors:  Marie-Laure Fogeron; Hannah Müller; Sophia Schade; Felix Dreher; Verena Lehmann; Anne Kühnel; Anne-Kathrin Scholz; Karl Kashofer; Alexandra Zerck; Beatrix Fauler; Rudi Lurz; Ralf Herwig; Kurt Zatloukal; Hans Lehrach; Johan Gobom; Eckhard Nordhoff; Bodo M H Lange
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

Review 10.  Galectin-4 in normal tissues and cancer.

Authors:  Margaret E Huflejt; Hakon Leffler
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.